



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

August 28, 2020

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

Scrip Code: 500124

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

Further to our press release dated November 6, 2015 with regard to the receipt of Warning Letter from US FDA for three of our sites (API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalguda, Telangana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh); we have now been informed by US FDA that based on its evaluation, we have addressed the violations and deviations contained in the said Warning Letter.

With this the said Warning Letter has been closed.

This is for your information.

With regards,

Sandeep Poddar
Company Secretary
CC:- New York Stock Exchange Inc.(Stock Code :RDY)